In-silico Predicted New Lead Molecules for Type-2 Diabetes Mellitus Targeting Aldose Reductase

n spite of insulin treatment, most diabetic patient eventually experience long term diabetic complication such as retinopathy, neuropathy, cataract and angiopathy. Aldose Reductase (AR) is widely expressed aldehyde-metabolizing enzyme which reduces glucose by the AR-catalyzed polyol pathway and linked to development of diabetic complication. The receptor protein structure of Aldose reductase was used and new ligand molecules were generated using structure based de novo approach. Here we report some potential lead molecules against the receptor binding site of aldose reductase based on the in silico docking between the ligand and the protin molecule. Developed ligands were optimized according to the bio-safety parameters.